Heart failure nasal spray trial pulled before it began

NCT ID NCT07375212

Terminated Symptom relief Sponsor: Prisma Health-Upstate Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a single dose of bumetanide given as a nasal spray could quickly lower blood pressure in the lungs and reduce blood volume in people with heart failure. Participants would have had a heart monitor implanted. However, the trial was withdrawn before enrolling anyone, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bumetanide (intranasal)
What this could lead to: If it works, this could point toward a convenient, non-injectable way to manage fluid overload in heart failure patients at home.
What could go wrong: This trial was withdrawn before enrolling anyone, so no data exist. Even if run, it was a small pilot study with a single dose, so results would be very preliminary and may not lead to a practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE，CONGESTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE，CONGESTIVE

Contacts and locations

Locations

Prisma Health

Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.